Lantern Pharma (NASDAQ: LTRN) announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney and thyroid cancers using its investigational therapy LP-184 (zirdafulven) based on a three-gene biomarker signature. The allowed claims cover the use of elevated expression of PTGR1, PTPN14 and ASPH to identify patients who may benefit from treatment with LP-184.
Lantern said its RADR® artificial intelligence platform helped identify the biomarker signature used in the patent, supporting the development of a precision medicine approach for LP-184. The company reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial and plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio. The full press release is available at https://ibn.fm/LRGUo.
This patent allowance is significant because it validates Lantern's AI-driven approach to drug development. The biomarker signature identified by RADR® enables precise patient selection, potentially increasing treatment efficacy and reducing side effects. For investors, this strengthens Lantern's intellectual property moat and supports the clinical advancement of LP-184, which is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR® platform to transform the development of cancer therapies. Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. With Zeta.ai, Lantern’s multi-agentic AI co-scientist platform, now commercially available, the company has a new revenue stream. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.
The implications of this announcement extend beyond Lantern. It demonstrates the potential of AI in precision oncology, potentially accelerating the development of targeted therapies. For patients with ovarian, liver, kidney, and thyroid cancers, this could lead to more effective treatment options. The biomarker-based approach aligns with the broader trend toward personalized medicine, where treatments are tailored to individual genetic profiles.
